Home About Us Services Markets Online Trading Back Office Contact Us Download Mutual Fund
Your are on :  Markets   |  News Analysis    |  Corporate News   |Detailed News   
Back
Thyrocare to acquire diagnostic and pathological services of Vimta Lab
30-Aug-24   12:17 Hrs IST

Thyrocare Technologies has signed a Business Transfer Agreement for purchase of the diagnostic and pathological services business of Vimta Labs.

Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs 30 crore during FY 2024 and Rs 7 crore in Q1 FY 2025.

Powered by Capital Market - Live News
Product Disclaimer Mandatory Information Privacy Policy Careers Risk disclosures Feedback Scores 2.0
Investor Charter
STOCK BROKER DEPOSITORY PARTICIPANTS INVESTOR GRIEVANCES ESCALATION MATRIX
Member Bank Details
"Investor Grievance" Mail your Grievance to info@lalkar.in
Important Links:   SEBI  |  NSE  |  BSE  |  MCX-SX  |  MCX   |   NCDEX  |  NSDL  |  CDSL  |  FMC   |   CDSL E-Voting  |  SMART ODR|  Saa₹thi  |  View Client Collateral Details  |  
Vernacular Languages  |  Online Freezing/Blocking Account  |  Advisory for Investor
SEBI REGISTRATION NOS - BSE CASH: INZ000269434  |  BSE FNO: INZ000269434  |  NSE CASH: INZ000269434  |  NSE FNO: INZ000269434  |  NSE CD: INZ000269434  |  MSEI CASH: INZ000269434   |   MSEI FNO: INZ000269434   |   MSEI CD: INZ000269434
AMFI NO : ARN- 19226
2010 © Lalkar Group. All rights reserved Designed, developed & powered by CMOTS Infotech(ISO 9001:2015 certified)